TORONTO, May 19 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of
contract development and manufacturing services to the global pharmaceutical
industry, announced today that it will report its second quarter 2009
financial results on Friday, June 12, 2009.
In conjunction with this announcement, Patheon will host a conference
call with financial analysts on Friday, June 12, 2009 at 10:00 a.m. (EST) to
discuss its second quarter 2009 financial results. The second quarter
financial results news release will be issued at approximately 7:00 a.m. (EST)
on Friday, June 12, 2009.
Interested parties are invited to access the live call, via telephone, in
listen-only mode, at (416) 644-3414 (Toronto and International) or toll free
at (800) 733-7560 (U.S., including Puerto Rico). Listeners are encouraged to
dial in five to fifteen minutes in advance to avoid delays. A live audio will
also be available via the web at www.patheon.com. (Please note that Windows
Media Player or RealPlayer is required.)
A telephone replay of the conference call will be available between
Friday, June 12, 2009 and Friday, June 19, 2009 by calling (416) 640-1917 or
(877) 289-8525 (toll free) and entering identification number 21306397,
followed by the number key. The webcast will also be archived on
www.patheon.com for three months.
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading provider of contract
development and manufacturing services to the global pharmaceutical industry.
Patheon prides itself in providing the highest quality products and services
to more than 300 of the world's leading pharmaceutical and biotechnology
companies. Patheon's services range from preclinical development through
commercial manufacturing of a full array of dosage forms including parenteral,
solid, semi-solid and liquid forms. Patheon uses many innovative technologies
including single-use disposables, liquid-filled hard capsules and a variety of
modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
Patheon's integrated development and manufacturing network of 11
facilities, and 6 development centers across North America and Europe, strives
to ensure that customer products can be launched with confidence anywhere in
For further information:
For further information: Mr. Eric Evans, Chief Financial Officer, Tel:
(919) 226-3204, Email: firstname.lastname@example.org; Ms. Doaa A. Fathallah, Senior
Vice President, General Counsel - Europe, Global PDS & Corporate Secretary,
Tel: +41 79 404 3085, Email: email@example.com